ATTR-CM Mechanism of Disease – Compliance Alert

Lower Risk

This Disease Education video is within acceptable compliance thresholds.

Analysis of this 304s Disease Education video identified 2 enforcement patterns, primarily Efficacy. Patterns span Efficacy — “Comparative Claims” identified at 207.8s, previously cited in NEXLIZET, COBENFY.

Recommended action: Initiate PromoMats review: Verify all efficacy claims against current approved labeling. Visual representations should align with clinical trial results referenced in the PI.

Video Timeline

Risk disclosure: 29.4s – 212.9s (183.5s of 303.6s total — 60.4% of ad)

Risk Window

0s76s152s228s304s

No visual distractions detected

Risk Window?

Patterns Detected (2)

Each pattern below is a known FDA enforcement concern, identified by matching this ad against 14 violation types from 34 FDA warning letters

Pattern	Dimension	Score	Evidence	CFR
Comparative Claims Claims suggesting superiority without adequate supporting data	Efficacy	69	3 clips	21 CFR 202.1(e)(5)	▶
FDA Concern: Advertisements cannot be false or misleading in any particular Previously cited: NEXLIZET, COBENFY
Dramatic Before/After Before/after visuals that may overstate treatment outcomes	Efficacy	69		21 CFR 202.1(e)(5)	▶
FDA Concern: Advertisements cannot be false or misleading in any particular Previously cited: TURALIO, TREMFYA

Compliance Alert: ATTR-CM Mechanism of Disease

Recommendations